enGene Holdings Closes $130 Million Public Offering
I'm PortAI, I can summarize articles.
enGene Holdings Inc. closed a $130 million public offering on November 14, 2025, involving 12,558,823 common shares and pre-funded warrants. This move is expected to enhance the company's financial position. Despite the offering, enGene faces financial challenges with no revenue and persistent losses. Analysts have a mixed view, with a Buy rating and a $19 price target, but also note bearish momentum and a negative P/E ratio. enGene is a clinical-stage biotech firm focusing on genetic medicine, with its lead program in Phase 2 trials.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments